258 related articles for article (PubMed ID: 28531261)
21. Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women.
Onuki M; Yamamoto K; Yahata H; Kanao H; Yokota H; Kato H; Shimamoto K; Takehara K; Kamiura S; Tsuda N; Takei Y; Shigeta S; Matsumura N; Yoshida H; Motohara T; Watari H; Nakamura K; Ueda A; Tasaka N; Ishikawa M; Hirashima Y; Kudaka W; Taguchi A; Iwata T; Takahashi F; Kukimoto I; Yoshikawa H; Yaegashi N; Matsumoto K;
Cancer Sci; 2022 Apr; 113(4):1428-1434. PubMed ID: 35043515
[TBL] [Abstract][Full Text] [Related]
22. High-Risk human papillomavirus genotype distribution in the Northern region of Portugal: Data from regional cervical cancer screening program.
Sousa H; Tavares A; Campos C; Marinho-Dias J; Brito M; Medeiros R; Baldaque I; Lobo C; Leça L; Monteiro P; Tavares F; Henrique R
Papillomavirus Res; 2019 Dec; 8():100179. PubMed ID: 31377173
[TBL] [Abstract][Full Text] [Related]
23. Human papillomavirus prevalence and vaccine effectiveness in young women in Germany, 2017/2018: results from a nationwide study.
Loenenbach A; Schönfeld V; Takla A; Wiese-Posselt M; Marquis A; Thies S; Sand M; Kaufmann AM; Wichmann O; Harder T
Front Public Health; 2023; 11():1204101. PubMed ID: 37719724
[TBL] [Abstract][Full Text] [Related]
24. Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study.
Man I; Georges D; de Carvalho TM; Ray Saraswati L; Bhandari P; Kataria I; Siddiqui M; Muwonge R; Lucas E; Berkhof J; Sankaranarayanan R; Bogaards JA; Basu P; Baussano I
Lancet Oncol; 2022 Nov; 23(11):1419-1429. PubMed ID: 36174583
[TBL] [Abstract][Full Text] [Related]
25. HPV prevalence and genotype distribution among women in Shandong Province, China: Analysis of 94,489 HPV genotyping results from Shandong's largest independent pathology laboratory.
Jiang L; Tian X; Peng D; Zhang L; Xie F; Bi C; Wang R; Wang J; Qi D
PLoS One; 2019; 14(1):e0210311. PubMed ID: 30653566
[TBL] [Abstract][Full Text] [Related]
26. HPV genotype distribution in older Danish women undergoing surgery due to cervical cancer.
Hammer A; Mejlgaard E; Gravitt P; Høgdall E; Christiansen P; Steiniche T; Blaakaer J
Acta Obstet Gynecol Scand; 2015 Nov; 94(11):1262-8. PubMed ID: 26300424
[TBL] [Abstract][Full Text] [Related]
27. Distribution of the most common types of HPV in Iranian women with and without cervical cancer.
Farahmand Z; Soleimanjahi H; Garshasbi M; Hasanzadeh M; Zafari E
Women Health; 2021 Jan; 61(1):73-82. PubMed ID: 32957835
[TBL] [Abstract][Full Text] [Related]
28. A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination.
Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Pearse A; Montoya GD; Robertson M; Shearman CA; Castle PE;
Int J Cancer; 2013 Jan; 132(1):198-207. PubMed ID: 22532127
[TBL] [Abstract][Full Text] [Related]
29. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
Arbyn M; Benoy I; Simoens C; Bogers J; Beutels P; Depuydt C
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515
[TBL] [Abstract][Full Text] [Related]
30. Pre-vaccination prevalence and genotype distribution of human papillomavirus infection among women from urban Tunis: a cross-sectional study.
Guettiti H; Ennaifer E; Attia L; Chelly D; Alaya NB; Aissa RB; Laassili T; Boubaker S
Asian Pac J Cancer Prev; 2014; 15(21):9361-5. PubMed ID: 25422225
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus genotypes among females in Mexico: a study from the Mexican institute for social security.
Salcedo M; Pina-Sanchez P; Vallejo-Ruiz V; Monroy-Garcia A; Aguilar-Lemarroy A; Cortes-Gutierrez EI; Santos-Lopez G; Montoya-Fuentes H; Grijalva R; Madrid-Marina V; Apresa-Garcia T; Hernandez DM; Jave-Suarez LF; Romero P; Poot A; Salgado E; Ramos-Gonzalez P; Gonzalez-Hernandez R; Canton JC; Jimenez-Aranda L; Parra-Melquiadez M; Paniagua L; Mendoza M; Arreola H; Villegas V; Torres-Poveda K; Bahena-Roman M; Gonzalez-Yebra B; Taniguchi K; Rodea C; Mantilla-Morales A; Mora-Garcia ML; Velazquez-Velazquez CK; Cordova-Uscanga C; Peralta R; Lopez-Romero R; Marrero D; Bandala C; Reyes-Leyva J; Furuya ME; Almeida E; Galvan ME; Grijalva I
Asian Pac J Cancer Prev; 2014; 15(23):10061-6. PubMed ID: 25556426
[TBL] [Abstract][Full Text] [Related]
32. Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence.
Carozzi F; De Marco L; Gillio-Tos A; Del Mistro A; Girlando S; Baboci L; Trevisan M; Burroni E; Grasso S; Giorgi Rossi P; Ronco G;
J Clin Virol; 2014 Jul; 60(3):257-63. PubMed ID: 24815381
[TBL] [Abstract][Full Text] [Related]
33. Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention?
Kjær SK; Munk C; Junge J; Iftner T
Cancer Causes Control; 2014 Feb; 25(2):179-89. PubMed ID: 24242002
[TBL] [Abstract][Full Text] [Related]
34. Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade After the Introduction of the HPV Vaccine.
Ährlund-Richter A; Cheng L; Hu YOO; Svensson M; Pennhag AAL; Ursu RG; Haeggblom L; Grün N; Ramqvist T; Engstrand L; Dalianis T; Du J
Front Cell Infect Microbiol; 2019; 9():59. PubMed ID: 30949454
[No Abstract] [Full Text] [Related]
35. Human papillomavirus genotypes and infection among women in Changzhou, China.
Geng Y; Liu L
Hum Vaccin Immunother; 2019; 15(7-8):1884-1888. PubMed ID: 31116690
[TBL] [Abstract][Full Text] [Related]
36. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
de Sanjose S; Quint WG; Alemany L; Geraets DT; Klaustermeier JE; Lloveras B; Tous S; Felix A; Bravo LE; Shin HR; Vallejos CS; de Ruiz PA; Lima MA; Guimera N; Clavero O; Alejo M; Llombart-Bosch A; Cheng-Yang C; Tatti SA; Kasamatsu E; Iljazovic E; Odida M; Prado R; Seoud M; Grce M; Usubutun A; Jain A; Suarez GA; Lombardi LE; Banjo A; Menéndez C; Domingo EJ; Velasco J; Nessa A; Chichareon SC; Qiao YL; Lerma E; Garland SM; Sasagawa T; Ferrera A; Hammouda D; Mariani L; Pelayo A; Steiner I; Oliva E; Meijer CJ; Al-Jassar WF; Cruz E; Wright TC; Puras A; Llave CL; Tzardi M; Agorastos T; Garcia-Barriola V; Clavel C; Ordi J; Andújar M; Castellsagué X; Sánchez GI; Nowakowski AM; Bornstein J; Muñoz N; Bosch FX;
Lancet Oncol; 2010 Nov; 11(11):1048-56. PubMed ID: 20952254
[TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus distribution in invasive cervical carcinoma in sub-Saharan Africa: could HIV explain the differences?
Ndiaye C; Alemany L; Ndiaye N; Kamaté B; Diop Y; Odida M; Banjo K; Tous S; Klaustermeier JE; Clavero O; Castellsagué X; Bosch FX; Trottier H; de Sanjosé S
Trop Med Int Health; 2012 Dec; 17(12):1432-40. PubMed ID: 23107344
[TBL] [Abstract][Full Text] [Related]
38. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
Poljak M; Seme K; Maver PJ; Kocjan BJ; Cuschieri KS; Rogovskaya SI; Arbyn M; Syrjänen S
Vaccine; 2013 Dec; 31 Suppl 7():H59-70. PubMed ID: 24332298
[TBL] [Abstract][Full Text] [Related]
39. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Kim JJ; Burger EA; Sy S; Campos NG
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
